Search by Categories
- Insights
- Rare Disease
- Oncology
- Cell and Gene Therapy
- Medical Devices
- Consulting
- News & Analysis
- Therapeutic Areas
Our expertise in the industry
Bristol-Meyers Squibb and Acceleron Pharma have announced that US FDA committee will review BMS’s supplemental Biologics License Application (sBLA) for its Reblozyl in MDS.Reblozyl ((luspater...
Keytruda wins FDA nod for treating Kidney CancerMerck’s Keytruda has recently got the U.S. FDA approval to be administered for Kidney Cancer. The drug Keytruda was approved in combination with...
Partnership between Bristol Meyers Squibb and AbbVie aims to evaluate the Combination of Rova-T plus Opdivo and Opdivo plus Yervoy Regimen Bristol Meyers Squibb and AbbVie have undergone an oncolog...
Human Immunodeficiency Virus or HIV is a species of Lentivirus (genus of retrovirus) th...
Progress is driven by innovation. When it comes to developing novel medications and the...
The HIV-1 treatment market for naïve and experienced patients is evolving consistently....
The Pharmaceuticals segment of the Healthcare Industry has a significant market across ...
Von Willebrand disease is a type of blood disorder that causes the blood to clot improp...
Hear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
